• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

系统给予棘白菌素类药物对在大鼠皮下模型中形成的体内成熟白色念珠菌生物膜的活性。

Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model.

机构信息

Department of Molecular Microbiology, VIB, KU Leuven, Leuven, Belgium.

出版信息

Antimicrob Agents Chemother. 2013 May;57(5):2365-8. doi: 10.1128/AAC.02288-12. Epub 2013 Feb 12.

DOI:10.1128/AAC.02288-12
PMID:23403433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3632894/
Abstract

This study addresses the effects of micafungin, caspofungin, and anidulafungin against Candida albicans biofilms developed in a subcutaneous catheter rat model system. Doses of 5, 10, and 30 mg/kg (of body weight)/day (the last only for micafungin) were given intravenously for 5, 7, and 10 days. All three echinocandins caused a significant reduction of the Candida cell numbers on the implanted catheters and are thus promising for the treatment of biofilm-related infections.

摘要

本研究旨在探讨米卡芬净、卡泊芬净和阿尼芬净对皮下留置导管大鼠模型系统中白色念珠菌生物膜的影响。分别给予 5、10 和 30mg/kg（仅米卡芬净为体重）/天的剂量，连续静脉给药 5、7 和 10 天。三种棘白菌素均显著降低了植入导管上的念珠菌细胞数量，因此有望用于治疗生物膜相关感染。

相似文献

1
Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model.系统给予棘白菌素类药物对在大鼠皮下模型中形成的体内成熟白色念珠菌生物膜的活性。
Antimicrob Agents Chemother. 2013 May;57(5):2365-8. doi: 10.1128/AAC.02288-12. Epub 2013 Feb 12.
2
In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis.一种新型导管相关性念珠菌病大鼠模型中阿尼芬净对成熟白色念珠菌生物膜的体内疗效。
Antimicrob Agents Chemother. 2010 Oct;54(10):4474-5. doi: 10.1128/AAC.00697-10. Epub 2010 Jul 26.
3
Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii.卡泊芬净在导管封管浓度下可根除葡萄牙念珠菌和季也蒙念珠菌的成熟生物被膜。
Antimicrob Agents Chemother. 2014 Aug;58(8):4953-6. doi: 10.1128/AAC.03117-14. Epub 2014 Jun 2.
4
In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth.卡泊芬净或米卡芬净导管封管溶液对白色念珠菌生物膜生长的体外疗效。
J Antimicrob Chemother. 2008 Jul;62(1):153-5. doi: 10.1093/jac/dkn160. Epub 2008 Apr 10.
5
The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms.非甾体类抗炎药双氯芬酸增强了卡泊芬净对白色念珠菌生物膜的体内活性。
J Infect Dis. 2012 Dec 1;206(11):1790-7. doi: 10.1093/infdis/jis594. Epub 2012 Sep 14.
6
In vitro activity of anidulafungin against Candida albicans biofilms.阿尼芬净对白色念珠菌生物被膜的体外活性。
Antimicrob Agents Chemother. 2008 Jun;52(6):2242-3. doi: 10.1128/AAC.00211-08. Epub 2008 Apr 7.
7
Antifungal lock therapy.抗真菌锁治疗。
Antimicrob Agents Chemother. 2013 Jan;57(1):1-8. doi: 10.1128/AAC.masthead.57-1. Epub 2012 Oct 15.
8
In vitro activity of micafungin against biofilms of Candida albicans, Candida glabrata, and Candida parapsilosis at different stages of maturation.米卡芬净对白色念珠菌、光滑念珠菌和近平滑念珠菌不同成熟阶段生物膜的体外活性。
Folia Microbiol (Praha). 2018 Mar;63(2):209-216. doi: 10.1007/s12223-017-0555-2. Epub 2017 Oct 5.
9
Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin.不同条件下白念珠菌和光滑念珠菌生物膜的详细比较及其对卡泊芬净和阿尼芬净的敏感性。
J Med Microbiol. 2011 Sep;60(Pt 9):1261-1269. doi: 10.1099/jmm.0.032037-0. Epub 2011 May 12.
10
Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production.白色念珠菌生物被膜对卡泊芬净和阿尼芬净的敏感性不受代谢活性或生物量产生的影响。
Med Mycol. 2016 Feb;54(2):155-61. doi: 10.1093/mmy/myv094. Epub 2015 Nov 5.

引用本文的文献

1
Combination of Systemic and Lock-Therapies with Micafungin Eradicate Catheter-Based Biofilms and Infections Caused by and in Neutropenic Rabbit Models.在中性粒细胞减少的兔模型中，米卡芬净的全身治疗与锁疗法联合使用可根除由[未提及的两种病原体]引起的基于导管的生物膜和感染。
J Fungi (Basel). 2024 Apr 17;10(4):293. doi: 10.3390/jof10040293.
2
[Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation(2023)].《造血干细胞移植患者侵袭性真菌病中国专家共识（2023年版）》
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):92-97. doi: 10.3760/cma.j.issn.0253-2727.2023.02.002.
3
Bioactive Peptides Against Fungal Biofilms.抗真菌生物膜的生物活性肽
Front Microbiol. 2019 Oct 4;10:2169. doi: 10.3389/fmicb.2019.02169. eCollection 2019.
4
Effect of Shikonin Against Biofilms.紫草素对生物膜的作用。
Front Microbiol. 2019 May 14;10:1085. doi: 10.3389/fmicb.2019.01085. eCollection 2019.
5
Transcriptomic and Genomic Approaches for Unravelling Biofilm Formation and Drug Resistance-An Update.用于揭示生物膜形成和耐药性的转录组学和基因组学方法——最新进展
Genes (Basel). 2018 Nov 7;9(11):540. doi: 10.3390/genes9110540.
6
Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.抗真菌和抗生物膜剂以及表面涂层针对真菌生物膜的作用方法及疗效评估
Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638.
7
Pharmacodynamic and Immunomodulatory Effects of Micafungin on Host Responses against Biofilms of Candida parapsilosis in Comparison to Those of Candida albicans.米卡芬净对近平滑念珠菌生物膜宿主反应的药效学和免疫调节作用与白念珠菌的比较。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00478-18. Print 2018 Aug.
8
Antifungal Activity of Oleylphosphocholine on and Biofilms.油基磷酸胆碱对 和 生物膜的抗真菌活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01767-17. Print 2018 Jan.
9
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis.抗真菌治疗：真菌病认识与治疗的新进展
Front Microbiol. 2017 Jan 23;8:36. doi: 10.3389/fmicb.2017.00036. eCollection 2017.
10
Inhibitory activity of hinokitiol against biofilm formation in fluconazole-resistant Candida species.扁柏酚对氟康唑耐药念珠菌生物膜形成的抑制活性。
PLoS One. 2017 Feb 2;12(2):e0171244. doi: 10.1371/journal.pone.0171244. eCollection 2017.

本文引用的文献

1
In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis.一种新型导管相关性念珠菌病大鼠模型中阿尼芬净对成熟白色念珠菌生物膜的体内疗效。
Antimicrob Agents Chemother. 2010 Oct;54(10):4474-5. doi: 10.1128/AAC.00697-10. Epub 2010 Jul 26.
2
Development and validation of an in vivo Candida albicans biofilm denture model.体内白念珠菌生物膜义齿模型的建立与验证。
Infect Immun. 2010 Sep;78(9):3650-9. doi: 10.1128/IAI.00480-10. Epub 2010 Jul 6.
3
Candida albicans biofilm formation in a new in vivo rat model.白色念珠菌生物膜在新型体内大鼠模型中的形成。
Microbiology (Reading). 2010 Mar;156(Pt 3):909-919. doi: 10.1099/mic.0.033530-0. Epub 2009 Dec 3.
4
Echinocandins: the newest class of antifungals.棘白菌素类：最新一类抗真菌药物。
Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1.
5
Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis.在新型念珠菌病小鼠中心静脉导管模型中用卡泊芬净治疗和预防白色念珠菌生物膜
J Antimicrob Chemother. 2009 Sep;64(3):567-70. doi: 10.1093/jac/dkp242. Epub 2009 Jul 7.
6
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.念珠菌病管理临床实践指南：美国传染病学会2009年更新版
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
7
Pharmacokinetics and tissue distribution of anidulafungin in rats.阿尼芬净在大鼠体内的药代动力学及组织分布
Antimicrob Agents Chemother. 2008 Jul;52(7):2673-6. doi: 10.1128/AAC.01596-07. Epub 2008 Apr 28.
8
Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model.在实验性血管内导管感染模型中评价卡泊芬净和两性霉素B脱氧胆酸盐对白色念珠菌生物膜的作用。
J Infect Dis. 2006 Sep 1;194(5):710-3. doi: 10.1086/506452. Epub 2006 Jul 28.
9
Pharmacokinetics/pharmacodynamics of echinocandins.棘白菌素类的药代动力学/药效学
Eur J Clin Microbiol Infect Dis. 2004 Nov;23(11):805-12. doi: 10.1007/s10096-004-1228-z. Epub 2004 Oct 14.
10
Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.给大鼠静脉注射抗真菌药物米卡芬净后的组织分布。
Biol Pharm Bull. 2004 Jul;27(7):1154-6. doi: 10.1248/bpb.27.1154.